TMC-310911

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H53N5O7S2
Molecular Weight	755.987
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC3=CC=CC=C3)[C@H](O)CN(CC(C)C)S(=O)(=O)C4=CC=C5N=C(NC6CCN(CC6)C7CCCC7)SC5=C4

InChI

InChIKey=JQUNFHFWXCXPRK-AMMMHQJVSA-N

InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00838162 | https://adisinsight.springer.com/drugs/800031712

ASC-09 orTMC-310911, a HIV protease inhibitor, participated in phase II clinical for the treatment of Human Immunodeficiency Virus Type 1. However, no recent development has been reported.

Originator

Approval Year

Sample Use Guides

In Vivo Use Guide

75 mg twice daily orally (by mouth) on Days 1 to 14.

Route of Administration: Oral

Name

Type

Language

TMC-310911

Code

English

((3AS,4R,6AR)-2,3,3A,4,5,6A-HEXAHYDROFURO(2,3-B)FURAN-4-YL) N-((1S,2R)-1-BENZYL-3-((2-((1-CYCLOPENTYL-4-PIPERIDYL)AMINO)-1,3-BENZOTHIAZOL-6-YL)SULFONYL-ISOBUTYL-AMINO)-2-HYDROXY-PROPYL)CARBAMATE

Systematic Name

English

CARBAMIC ACID, N-((1S,2R)-3-(((2-((1-CYCLOPENTYL-4-PIPERIDINYL)AMINO)-6-BENZOTHIAZOLYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER

Systematic Name

English

ASC 09 [WHO-DD]

Common Name

English

ASC-09

Code

English

ASC09

Code

English

TMC310911

Code

English

Code System Code Type Description

SMS_ID

300000021735